AB0616 HISPANIC AMERICAN PATIENTS WITH ANCA ASSOCIATED VASCULITIS AND DIFFUSE ALVEOLAR HEMORRHAGE RESPOND COMPARABLY TO INDUCTION THERAPY

Background: Hispanic american patients with aNCA-associated vasculitis (AAV) have been reported to have more severe disease and higher damage indices at presentation. One rare but life-threatening complication of aAV is diffuse alveolar hemorrhage (DAH). Objectives: To study the clinical features, course and response to therapy in Hispanic american patients with aAV and DAH seen at a large public teaching hospital that serves medically underserved and low income patients with chronic poor health maintenance. Methods: Among 60 Hispanic american patients with aAV, we retrospectively studied 13 patients with DAH from 2003-2017. Clinical features, laboratory results, diagnostic modalities and treatments given were studied. Results: A total of 13 patients were identified; 6 men and 7 women, mean age of 51± 11 years. Anti-PR3 was found in 5 patients, anti-MPO in 8. Nine patients were diagnosed with microscopic polyangiitis and 4 with granulomatous polyangiitis based on aCR criteria or Chapel Hill Consensus Conference definitions. DAH was a presenting manifestation in 12 patients. Gross hemoptysis with hypoxia, drop in hematocrit and chest X-ray infiltrates were seen in all patients diagnosed with DAH. Bronchoscopy with BAL washings confirming diagnosis was done in 10 patients. All patients had multi-organ involvement including nephritis (n= 8), peripheral neuropathy (n= 1), palpable purpura (n=2), upper respiratory tract involvement (n= 4) and eye involvement (n=2). Serum C3 was normal in 12 patients. Renal biopsy in 9 patients showed pauci-immune crescentic glomerulonephritis. Mean BVAS at time of DAH was 21.2 ± 5.1. All patients underwent induction-remission therapy with pulse methylprednisolone followed by tapering oral prednisone. Induction therapy included IV cyclophosphamide (n=6), rituximab (n=6) and IV cyclophosphamide/rituximab combination therapy (n=1). Nine patients underwent plasma exchange and 5 received IV gamma globulin. Eleven patients required mechanical ventilation; 6 patients needed hemodialysis, 2 temporarily. All 13 patients responded to induction therapy; mean post-induction therapy BVAS was 9.3 ± 3.5. Pulmonary fibrosis after DAH was noted in 2 patients. No early deaths ( Five patients had clinical relapse, 3 with recurrent DAH. Two patients had minor relapse, defined by their treating physician as requiring increased prednisone dose or worsening proteinuria. Mean BVAS at relapse was 15.2 ± 5.5. Conclusion: This first in-depth study of DAH in Hispanic american aAV patients shows that in this socioeconomically disadvantaged patient population, the response to induction therapy is not significantly different from other ethnic groups reported in the literature. DAH remains a severe clinical manifestation of aAV and should be recognized without delay. If treated promptly following EULAR/ERA-EDTA recommendations, good short term response is to be expected. References [1] Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of aNCA-associated vasculitis. Ann Rheum Dis2016;75:1583-1594 [2] Jennette JC, Falk RJ, Bacon PA, et al. 2012Revised international Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum2013;65:1-11 Disclosure of interests: None declared